47.60USD-4.68%Mkt Cap: —P/E: —1d ago
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse therm…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value2.37B $
Revenue (TTM)188.73M $
Gross Profit171.46M $
Net Income (TTM)-97.64M $
Revenue/Share3.815 USD
Last Price47.60 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees300
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-35.76
EV/Revenue12.57
P/S—
P/B-17.15
EPS (TTM)—
EPS (Forward)—
52W Range
47.357% of range51.11
52W High51.11 USD
52W Low47.35 USD
Profitability
Gross Margin90.84%
Oper. Margin0.15%
EBITDA Margin-35.15%
Profit Margin-51.73%
ROE—
ROA-18.06%
Growth
Revenue Growth199.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-158.92M $
CapEx (TTM)—
FCF Margin-56.68%
FCF Yield—
Net Debt88.15M $
Net Debt/EBITDA-1.33
Balance Sheet
Debt/Equity—
Current Ratio3.80
Quick Ratio3.18
Book Value/Sh-2.7090 USD
Cash/Share2.209 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.16.10M
Float43.35M
Insiders3.60%
Institutions93.21%
Technical
SMA 5016.10 (+195.6%)
SMA 20014.63 (+225.3%)
Beta1.57
S&P 52W Chg18.16%
Avg Vol (30d)10.75K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—